WebTANGENT REPROFILING LIMITED is an entity registered with the Companies House, Department for Business, Energy & Industrial Strategy, United Kingdom. The company number is #06704572. The business office address is The Walbrook Building, 25 Walbrook, London, EC4N 8AF, ENGLAND. Company Information. WebValiRx and Tangent Reprofiling Ltd to develop VAL401 in lung cancer and potentially other indications. ValiRx plc Annual Report and Accounts 2024 WELCOME TO VALIRX PLC. Operational Highlights • Period of substantive and encouraging development across
A2SP VentureRadar
Web( 73 ) Assignee : Tangent Reprofiling Limited , London ( GB ) OTHER PUBLICATIONS ( * ) Notice : Subject to any disclaimer , the term of this patent is extended or adjusted under 35 U . S . C . 154 ( b ) by 0 days . This patent is subject to a terminal dis claimer . ( 21 ) Appl . No . : 15 / 444 , 077 ( 22 ) Filed : Feb . 27 , 2024 Web(73) Assignee: Tangent Reprofiling Limited, London (GB) (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. This patent is Subject to a terminal dis claimer. (22) … brian forsythe midwest orthopedics
TANGENT REPROFILING LIMITED - getthedata.com
WebFeb 10, 2016 · Research by the University of Warwick, the University Hospital Coventry and Warwickshire NHS Trust (UHCW), and Tangent Reprofiling Limited, has discovered that … Web(71) Applicant: Tangent Reprofiling Limited, London filed on Sep. 26, 2012. (GB) Publication Classification (72) Inventors: Suzanne Dilly, Oxfordshire (GB); Gregory Stoloff, London (GB); Paul (51) Int. Cl. Taylor, London (GB) A 6LX3/59 (2006.01) A63L/20 (2006.01) (73) Assignee: Tangent Reprofiling Limited, London A613 L/454 (2006.01) ... WebJul 6, 2024 · ValiSeek Ltd., a JV formed between ValiRx plc (LSE:VAL) and the Tangent Reprofiling Ltd. subsidiary of Seek Ltd. (London, U.K.), completed enrollment of 8 patients in a Phase II trial of VAL401 to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of ≥1 prior chemotherapeutic regimen (see BioCentury, April 14, 2014). brian forsythe md npi